SCHEMBL21753546

SCHEMBL21753546

CCOC(=O)c1cn(C2CC2)nc(-c2ccc(F)cc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.45
GAA P10253 2/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
MAPT P10636 2/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTGS2 P35354 1/20 0.41
CSNK1D P48730 2/20 0.40
CSNK1E P49674 2/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753533 0.82 CSNK1D (0.47) CSF1RCSNK1DCSNK1EBTKMAPK14
SCHEMBL29902525 0.81 BTK (0.52) CSF1RCSNK1DCSNK1EBTKTGFBR1
SCHEMBL21753567 0.81 ADORA3 (0.47) CSF1RGAANPC1RAB9AALDH1A1
SCHEMBL22897232 0.80 MAPK1 (0.56) NPC1RAB9AALDH1A1KDM4EHPGD
SCHEMBL21753540 0.80 LMNA (0.46) GAANPC1RAB9AALDH1A1KDM4E
SCHEMBL18017552 0.78 BTK (0.52) GAANPC1RAB9AALDH1A1KDM4E
SCHEMBL20351780 0.77 ALDH1A1 (0.45) GAANPC1RAB9AALDH1A1KDM4E
SCHEMBL21816295 0.75 TSHR (0.42) NPC1RAB9AALDH1A1KDM4EMAPT
SCHEMBL22979067 0.75 KDM4E (0.42) ALDH1A1KDM4ELMNAHSD17B10CSNK1D
SCHEMBL15750457 0.74 NPC1 (0.51) GAANPC1RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3842425-B1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES NANJING INC (CN) 2024-05-22 EP disclosed
CN-110857293-B Novel quinoline derivative inhibitor 药捷安康(南京)科技股份有限公司 2023-01-10 CN disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
EP-3842425-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR Nanjing Transthera Biosciences Co., Ltd. (CN) 2021-06-30 EP disclosed
CN-110857293-A Novel quinoline derivative inhibitor 南京药捷安康生物科技有限公司 2020-03-03 CN disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed
WO-2020038460-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR 南京药捷安康生物科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR CSF1R, CSF3R, FLT3 CSF1R 1/4885GAA 1590/4885NPC1 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.